In-vitro and in-vivo correlation for two gliclazide extended-release tablets

Journal of Pharmacy and Pharmacology

Volumn 59, Issue 7, 2007, Pages 971-976

  Mandal, U ^a   Ray, K K ^a   Gowda, Veeran ^a   Ghosh, A ^a   Pal, T K ^a  

^a JADAVPUR UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

GLICLAZIDE;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CURVE FITTING; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG RELEASE; DRUG SOLUBILITY; EXTERNAL VALIDITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTERNAL VALIDITY; LINEAR REGRESSION ANALYSIS; MAXIMUM PLASMA CONCENTRATION; RANDOMIZED CONTROLLED TRIAL; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; GLICLAZIDE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MODELS, BIOLOGICAL; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; SOLUBILITY; TABLETS;

EID: 34447310826     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.59.7.0009     Document Type: Article

References (18)

1. Balan, G., Timmins, P., Greene, D. S., Marathe, P. H. (2001) In-vitro-in-vivo correlation (IVIVC) models for metformin after administration of modified-release (MR) oral dosage forms to healthy human volunteers. J. Pharm. Sci. 90: 1176-1185
2. Dalton, J. T., Straughn, A. B., Dickason, D. A., Grandolfi, G. P. (2001) Predictive ability of level A in-vitro-in vivo correlation for ringcap controlled release acetaminophen tablets. Pharm. Res. 18: 729-1734
3. Eddington, N. D., Marroum, P., Uppoor, R., Hessian, A., Augsburger, J. (1998) Development and internal validation of an in vitro in vivo correlation for a hydrophilic metoprolol tartrate extended release tablet formulation. Pharm. Res. 15: 466-473
4. FDA (1997) Extended release solid oral dosage forms: development, evaluation and application of in vitro/in vivo correlations, September1997. US Department of Health, Food and Drug Administration, Center for Drug Evaluation and Research (CDER)
5. Gibaldi, M., Perrier, D. (1982) Pharmacokinetics. 2nd Edn, Marcel Dekker Inc., New York
6. Glowka, F. K., Herman, T. W., Zabel, M. (1998) Bioavailability of gliclazide from some formulation tablets. Int. J. Pharm. 172: 71-77
7. Hermann, T. W., Dobrucki, R., Piechocki, S., Resztak, M., Reh, R. (2005) Pharmaceutical availability of gliclazide from selected matrix formulation tablets. Med. Sci. Monit. 11: 181-188
8. Hussein, Z., Friedman, M. (1990) Release and absorption characteristics of novel theophylline sustained release formulations in vitro-in vivo correlation. Pharm.Res. 7: 1167-1171
9. Kobayashi, K., Kimura, M., Sakoguchi, T., Hase, A., Matsuoka, A., Kaneko, S. (1984) Pharmacokinetics of gliclazide in healthy and diabetic subjects. J. Pharm. Sci. 73: 1684-1687
10. Mahayni, H., Rekhi, G. S., Upoor, R. S., Marroum, P., Hussian, A. S., Augsburger, I. I., Edington., N. D. (2000) Evaluation of "external" predictability of an in vitro-in vivo correlation for extended release formulation containing metoprolol tartrate. J. Pharm. Sci. 89: 1354-1361
11. Rackley, R. J. (1997) Examples of in vitro-in vivo relationships with a diverse range of quality. In: Young, D., Devane, J. G., Butler, J. (eds) In vitro in vivo correlations, advances in experimental medicine and biology. Vol. 423, Plenum Press, New York, pp 53-65
12. Roshdy, M. N., Schnaare, R. I., Sugita, E. T., Zietz, S., Schwartz, J. B. (2002) An adjusted pharmacokinetic equation for predicting drug levels in vivo based on in vitro square root of time release kinetics. Pharm Dev. Techol. 7: 203-213
13. Sirisuth N., Augsburger, L. L., Edington, N. D. (2002) Development and validation of a non-linear IVIVC model for a diltiazem extended release formulation. Biopharm. Drug Dispos. 23: 1-8
14. Skelley J. P., Amidon, G. L., Barr, W. H., Benet, I. Z., Carter, J. E., Robinson, J. R., Shah, V. P., Yacobi, A. (1990) Report of the workshop on in vitro and in vivo testing and correlation for oral controlled modified-release dosage forms. J. Pharm Sci. 79: 849-854
15. US Department of Health, Food and Drug Administration (1997) Dissolution testing of immediate release solid oral dosage forms, August 1997
16. USP Subcommittee on Biopharmaceutics (1988) In-vitro-in vivo correlation for extended release oral dosage forms. Pharm. Forum July-Aug: 4160-4161
17. Veng-Pedersen, P., Gobburu, J. V. S., Meyer, M. C., Straughn, A. B. (2000) Carbamazepine Level A in-vitro-in vivo correlation (IVIVC): a scaled convolution based predictive approach. Biopharm. Drug Dispos. 21: 1-6
18. Wagner, J. G. (1971) Biopharmaceutics and relevant pharmacokinetics. Drug intelligence Publishers. Illinois